| Not Yet Recruiting | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma Meningioma | Phase 2 | 2026-05-01 |
| Recruiting | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors Solid Tumors | Phase 1 | 2025-08-18 |
| Recruiting | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2 / Phase 3 | 2025-07-21 |
| Recruiting | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) Hepatic Impairment, Moderate Hepatic Impairment | Phase 1 | 2025-05-13 |
| Recruiting | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | 2025-05-01 |
| Terminated | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metasta Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy | Phase 1 | 2024-10-17 |
| Recruiting | Study of XB010 in Subjects With Solid Tumors Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer | Phase 1 | 2024-08-06 |
| Active Not Recruiting | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or M Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | 2024-06-07 |
| Recruiting | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2024-04-03 |
| Terminated | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Cle Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Phase 1 | 2024-01-25 |
| Active Not Recruiting | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carc Non-Clear Cell Renal Cell Carcinoma | Phase 3 | 2023-01-01 |
| Active Not Recruiting | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer Colorectal Cancer | Phase 3 | 2022-09-07 |
| Terminated | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL) | Phase 1 | 2022-04-12 |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC) | Phase 1 | 2021-12-14 |
| Completed | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Non Small Cell Lung Cancer, Cervical Cancer, SCCHN | Phase 1 | 2021-06-07 |
| Terminated | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 | 2021-02-10 |
| Active Not Recruiting | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Metastatic Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | 2020-10-19 |
| Active Not Recruiting | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advan Renal Cell Carcinoma | Phase 3 | 2019-06-25 |
| Active Not Recruiting | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma | Phase 1 | 2019-03-20 |
| Active Not Recruiting | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid C Differentiated Thyroid Cancer | Phase 3 | 2018-10-05 |
| Active Not Recruiting | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatoce Hepatocellular Carcinoma | Phase 3 | 2018-06-10 |
| Active Not Recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastati Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | 2017-09-05 |
| Active Not Recruiting | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Medullary Thyroid Cancer | Phase 4 | 2015-02-25 |
| Terminated | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms | Phase 2 | 2014-02-01 |
| Completed | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sor Hepatocellular Carcinoma | Phase 3 | 2013-09-26 |
| Completed | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma Renal Cell Carcinoma | Phase 3 | 2013-06-01 |
| Completed | A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Healthy, Renal Impairment | Phase 1 | 2012-12-01 |
| Completed | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Pr Prostate Cancer, Castration Resistant Prostate Cancer, Pain | Phase 3 | 2012-07-01 |
| Terminated | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic C Prostate Cancer, Castration Resistant Prostate Cancer, Pain | Phase 3 | 2012-03-01 |
| Completed | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects Healthy, Hepatic Impairment | Phase 1 | 2011-09-01 |
| Completed | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer Solid Tumors, Cancer, NSCLC | Phase 1 | 2011-02-01 |
| Completed | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid T Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer | Phase 1 | 2010-04-01 |
| Terminated | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Rel Astrocytic Tumors | Phase 2 | 2010-04-01 |
| Completed | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Tre Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma | Phase 1 | 2009-09-01 |
| Completed | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies Solid Tumors, Cancer | Phase 2 | 2009-09-01 |
| Terminated | Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors Cancer | Phase 1 | 2008-11-01 |
| Completed | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Thyroid Cancer | Phase 3 | 2008-06-01 |
| Withdrawn | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors Cancer, Non-small-cell Lung Cancer, Breast Cancer | Phase 1 | 2008-06-01 |
| Completed | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme Glioblastoma Multiforme | Phase 2 | 2008-05-01 |
| Completed | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2008-02-12 |
| Completed | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms | Phase 2 | 2007-12-01 |
| Terminated | A Phase 1 Study of XL019 in Adults With Polycythemia Vera Polycythemia Vera | Phase 1 | 2007-12-01 |
| Terminated | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies Cancer, Lymphoma | Phase 1 | 2007-09-01 |
| Terminated | A Safety Study of XL019 in Adults With Myelofibrosis Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera | Phase 1 | 2007-08-01 |
| Terminated | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Ma Cancer, Lymphoma | Phase 1 | 2007-05-01 |
| Terminated | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 | 2007-05-01 |
| Suspended | Study of XL418 in Adults With Solid Tumors Cancer, Solid Tumors | Phase 1 | 2007-04-01 |
| Completed | Study of XL281 in Adults With Solid Tumors Cancer, Non-small-cell Lung Cancer, Colorectal Cancer | Phase 1 | 2007-02-01 |
| Completed | Study of XL820 Given Orally Daily to Subjects With Solid Tumors Cancer | Phase 1 | 2006-07-01 |
| Completed | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Lymphoma, Cancer, Thyroid Carcinoma | Phase 1 | 2005-09-01 |
| Completed | Study of XL820 in Adults With Solid Tumors Cancer | Phase 1 | 2005-08-01 |
| Terminated | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | — |
| Approved For Marketing | Expanded Access of Cabozantinib in Medullary Thyroid Cancer Medullary Thyroid Cancer | — | — |